Verve Therapeutics
Focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $1.0b Valuation: $1.0b | Acquisition | |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 506 % | 175 % | 31 % | (46 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (8536 %) | (1851 %) | (686 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (8109 %) | (1702 %) | (615 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 6702 % | 1573 % | 632 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Verve Therapeutics is a pioneering genetic medicines company focused on transforming the treatment of cardiovascular disease through innovative gene editing technologies. The company operates in the biotechnology sector, specifically targeting cardiovascular health. Verve's business model revolves around discovering and developing single-course gene editing medicines that aim to provide long-term solutions for patients, as opposed to traditional chronic management therapies. The initial programs target the PCSK9 and ANGPTL3 genes, which are well-validated for their roles in lowering blood lipid levels. Verve Therapeutics primarily serves patients suffering from cardiovascular diseases, offering them potentially curative treatments. The company generates revenue through the development and commercialization of its gene editing therapies, as well as potential partnerships and collaborations with other biotech firms and healthcare providers.
Keywords: gene editing, cardiovascular disease, biotechnology, PCSK9, ANGPTL3, single-course treatment, genetic medicines, lipid lowering, innovative therapies, healthcare.